Bisantrene + Fludarabine + Clofarabine

Phase 2UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelogenous Leukemia, Acute

Conditions

Myelogenous Leukemia, Acute

Trial Timeline

Aug 2, 2021 → Dec 1, 2025

NCT ID

NCT04989335

About Bisantrene + Fludarabine + Clofarabine

Bisantrene + Fludarabine + Clofarabine is a phase 2 stage product being developed by Race Oncology for Myelogenous Leukemia, Acute. The current trial status is unknown. This product is registered under clinical trial identifier NCT04989335. Target conditions include Myelogenous Leukemia, Acute.

What happened to similar drugs?

8 of 20 similar drugs in Myelogenous Leukemia, Acute were approved

Approved (8) Terminated (1) Active (11)

✅micafungin + posaconazoleAstellas PharmaApproved

✅NilotinibNovartisApproved

✅imatinib mesylateNovartisApproved

✅NilotinibNovartisApproved

🔄NilotinibNovartisPhase 3

🔄nilotinib + imatinibNovartisPhase 3

🔄imatinib mesilate + interferon-alpha (INF-a) + cytarabine (ARA-C)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04989335	Phase 2	UNKNOWN	Aug 2, 2021	Dec 1, 2025	Myelogenous Leukemia, Acute

Competing Products

20 competing products in Myelogenous Leukemia, Acute

See all competitors

Product	Company	Stage	Hype Score
Bisantrene	Race Oncology	Phase 2	29
Milademetan + AZA + Milademetan	Daiichi Sankyo	Phase 1	21
micafungin + posaconazole	Astellas Pharma	Approved	43
decitabine Induction Chemotherapy + Induction Chemotherapy	Eisai	Phase 2	27
decitabine (5-aza-2'deoxycytidine)	Eisai	Phase 2	35
Decitabine	Eisai	Phase 2	35
Decitabine + Gemtuzumab ozogamicin	Eisai	Phase 2	35
Ondansetron + Palonosetron	Eisai	Phase 2	35
decitabine (5-aza-2'deoxycytidine)	Eisai	Phase 2	35
Decitabine + Decitabine	Eisai	Phase 2	27
Decitabine	Eisai	Phase 2/3	38
KW-2449	Kyowa Kirin	Phase 1	21
KW-2449	Kyowa Kirin	Phase 1	21
flumatinib + imatinib	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199	AbbVie	Phase 2	35
Posaconazole + ABT-199 + Decitabine + Azacitidine	AbbVie	Phase 1	21
Venetoclax + Cytarabine	AbbVie	Phase 1/2	32
AZD4877	AstraZeneca	Phase 1	21
MK-8776 + Cytarabine	Merck	Phase 1	21
MK0457	Merck	Phase 1	29